CYTOTOXIC T LYMPHOCYTES-INDUCTION AND ACTIVATION ...124 EPSTEIN BARR VIRUS ASSOCIATED TUMOURS ...125 Immunoblastic lymphomas ...126 Burkitt's lymphoma ...127 NPC and Hodgkin's lymphoma ...127 Vaccines for EBV associated malignancies ...128 HUMAN PAPILLOMA VIRUS (HPV) ASSOCIATED TUMOURS ...129 T cell responses against HPV ...130 Cytotoxic T cell responses in HPV infection ...130 Vaccines and clinical trials ...132 Recombinant viral vaccines ...132 Peptide vaccines ...133 Bacterial fusion protein vaccines ...134 Potential Pitfalls for CTL based immunotherapy of CaCX ...134 PROSPECTS FOR OTHER VIRALL Y ASSOCIATED CANCERS ...135 Hepatitis viruses and primary liver cancer ...135 Human herpes virus 8 and Kaposi's sarcoma ...136 Human T lymphotropic virus and adult T cell leukaemia ...136 Emerging tumour viruses ...137 CONCLUDING REMARKS ...137 ACKNOWLEDGEMENTS ...138 REFERENCES ...139 Chapter 8 ...147 The immune response to oncogenic fusion proteins LORENA PASSONI & CARLO GAMBACORTI-PASSERINI xiii INTRODUCTION ...147 BCRlABL ...149 CML immunotherapy ...150 Specific recognition of the bcr/abl protein ...150 CML vaccination ...152 FUSION PROTEINS AND TUMOUR ESCAPE ...1
52 CONCLUDING REMARKS ...154 REFERENCES ...154 Chapter 9 ...157 Immunological significance ofhsp70 in tumor rejection ANTOINE MENORET INTRODUCTION ...157 PROGRESSOR AND REGRESSOR TUMORS ...157 CO-SEGREGATION OF EXPRESSION OF THE INDUCIBLE HSP70, BUT NOT OF THE CONSTITUTIVE HSC70, WITH A REGRESSIVE PHENOTYPE ...159 IMMUNIZATION WITH TUMOR-DERIVED HEAT SHOCK PROTEIN OF 70 KDA (HSP70IHSC70), NA TURALL Y OR ARTIFICIALLY COMPLEXED WITH ANTIGENIC PEPTIDES ...161 DIFFERENCE OF PEPTIDE BINDING DOMAINS BETWEEN THE INDUCIBLE HSP70 AND CONSTITUTIVE HSC70 ...163 XIV IMPLICATION FOR IMMUNOTHERAPY OF CANCER AND BEYOND ...165 ACKNOWLEDGMENTS ...166 REFERENCES ...166 Chapter 10 ...